Vaxart Inc. (NB11)

Market Open

16 Jun, 13:43

XSTU

€

0. 59

+0.12

+25.21%

- Market Cap

- P/E Ratio

0% Div Yield

3,000 Volume

-0.45 Eps

€ 0.47

Previous Close

Day Range

0.58 0.65

Year Range

0.26 0.91

Summary

NB11 trading today higher at €0.59, an increase of 25.21% from yesterday's close, completing a monthly increase of 61.51% or €0.22. Over the past 12 months, NB11 stock lost -5.38%.

NB11 pays dividends to its shareholders, with the most recent payment made on Nov 08, 2012. The next estimated payment will be in 8 Nov 2012 on Nov 08, 2012 for a total of €12.188.

The last earnings report, released on May 12, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports.

The stock of the company had never split.

The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

Want to track NB11 and more in your Portfolio? 🎯

Get Started For Free

NB11 Chart

Loading, please wait...

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Preliminary results from the Annual Meeting indicate that two proposals were approved and two proposals were rejected by Vaxart stockholders.

Globenewswire | 4 days ago

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constructs, supporting potential for improved protection against infection -

Globenewswire | 1 week ago

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Meeting adjourned to June 13, 2025 at 8:30 a.m. Pacific Time Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m.

Globenewswire | 2 weeks ago

Vaxart Inc. Dividends

VXRT 9 Nov 2012 Paid	Other	$12.19 Per Share

NB11 dividends

Vaxart Inc. Earnings

12 May 2025 Date	- Cons. EPS	- EPS
12 Mar 2025 Date	- Cons. EPS	- EPS
31 Oct 2024 Date	- Cons. EPS	- EPS
8 Aug 2024 Date	- Cons. EPS	- EPS
1 Aug 2024 Date	- Cons. EPS	- EPS

NB11 earnings

Dividends
Earnings

VXRT 9 Nov 2012 Paid	Other	$12.19 Per Share

NB11 dividends

12 May 2025 Date	- Cons. EPS	- EPS
12 Mar 2025 Date	- Cons. EPS	- EPS
31 Oct 2024 Date	- Cons. EPS	- EPS
8 Aug 2024 Date	- Cons. EPS	- EPS
1 Aug 2024 Date	- Cons. EPS	- EPS

NB11 earnings

Vaxart Inc. (NB11) FAQ

What is the stock price today?

The current price is €0.59.

On which exchange is it traded?

Vaxart Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is NB11.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Vaxart Inc. ever had a stock split?

Vaxart Inc. had 0 splits and the recent split was on Feb 14, 2018.

Vaxart Inc. Profile

Biotechnology Industry	Healthcare Sector	Mr. Steven Lo CEO	XSTU Exchange	US92243A2006 ISIN
US Country	105 Employees	14 Feb 2018 Last Dividend	14 Feb 2018 Last Split	12 Feb 2018 IPO Date

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Contact Information

Address: 170 Harbor Way

Phone: 650 550 3500

Website: https://vaxart.com

Affiliate Program About Report a Bug Terms Privacy Help Contact Us